{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Bio-Path Holdings, Inc. overvalued or undervalued?
As of October 15, 2023, Bio-Path Holdings, Inc. is considered undervalued with a favorable P/E ratio of 12.5 compared to peers, strong financial ratios, and recent stock performance that has outpaced the market.
Is Bio-Path Holdings, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for Bio-Path Holdings, Inc. to determine a bullish or bearish outlook.
Who are in the management team of Bio-Path Holdings, Inc.?
As of March 2022, the management team of Bio-Path Holdings, Inc. includes Peter Nielsen (Chairman, CEO, Co-Founder, CFO), Douglas Morris (Director, Secretary), and independent directors Paul Aubert, Heath Cleaver, and Martina Molsbergen. They oversee the company's strategic direction and operations.
What does Bio-Path Holdings, Inc. do?
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology-focused company specializing in antisense drug development, with a market cap of USD 1.66 million and a recent net profit of -3 million. The company has no dividend yield and is currently loss-making.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
